Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Harding

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|December 25, 2024
Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: Results from iStopMM, a prospective population-based screening studySæmundur Rögnvaldsson, Alessandro Gasparini, Sigrun Thorsteinsdottir, et al.
Blood Cancer Journal|September 13, 2022
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM studyThorir Einarsson Long, Olafur Skuli Indridason, Runolfur Palsson, et al.
Archives of Dermatological Research|September 14, 2024
Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopeciaDivija Sharma, Benjamin Ungar, Jonas A Adalsteinsson, et al.
The British Journal of Dermatology|June 2, 2026
Monoclonal gammopathy of undetermined significance is not associated with increased risk of skin cancerJónas A Aðalsteinsson, Gauti Kjartan Gislasson, Styrmir Hallsson, et al.
Blood|December 19, 2024
Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening studyÁstrún Helga Jónsdóttir, Helga Ágústa Sigurjónsdóttir, Sigrun Thorsteinsdóttir, et al.
Leukemia|July 6, 2026
Redefining light-chain smoldering multiple myeloma: prevalence and progression riskCecilie Velsoe Maeng, Sigrún Thorsteinsdóttir, Jón Þórir Óskarsson, et al.
JAMA Oncology|May 29, 2025
New Definition of Light Chain Monoclonal Gammopathy of Undetermined SignificanceThorir Einarsson Long, Saemundur Rognvaldsson, Sigrun Thorsteinsdottir, et al.
Leukemia & Lymphoma|July 13, 2017
Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteriaGuillemette Fouquet, Kym Ie Snell, Stéphanie Guidez, et al.
Haematologica|January 11, 2024
Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and SwedenSæmundur Rögnvaldsson, Sigrun Thorsteinsdóttir, Elisavet Syriopoulou, et al.
Blood|November 21, 2024
Serum free light chains in a racially diverse population including African Americans and populations from South AfricaLuca Bertamini, Jean-Baptiste Alberge, David J Lee, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|December 25, 2024
Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: Results from iStopMM, a prospective population-based screening studySæmundur Rögnvaldsson, Alessandro Gasparini, Sigrun Thorsteinsdottir, et al.
Blood Cancer Journal|September 13, 2022
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM studyThorir Einarsson Long, Olafur Skuli Indridason, Runolfur Palsson, et al.
Archives of Dermatological Research|September 14, 2024
Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopeciaDivija Sharma, Benjamin Ungar, Jonas A Adalsteinsson, et al.
The British Journal of Dermatology|June 2, 2026
Monoclonal gammopathy of undetermined significance is not associated with increased risk of skin cancerJónas A Aðalsteinsson, Gauti Kjartan Gislasson, Styrmir Hallsson, et al.
Blood|December 19, 2024
Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening studyÁstrún Helga Jónsdóttir, Helga Ágústa Sigurjónsdóttir, Sigrun Thorsteinsdóttir, et al.
Leukemia|July 6, 2026
Redefining light-chain smoldering multiple myeloma: prevalence and progression riskCecilie Velsoe Maeng, Sigrún Thorsteinsdóttir, Jón Þórir Óskarsson, et al.
JAMA Oncology|May 29, 2025
New Definition of Light Chain Monoclonal Gammopathy of Undetermined SignificanceThorir Einarsson Long, Saemundur Rognvaldsson, Sigrun Thorsteinsdottir, et al.
Leukemia & Lymphoma|July 13, 2017
Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteriaGuillemette Fouquet, Kym Ie Snell, Stéphanie Guidez, et al.
Haematologica|January 11, 2024
Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and SwedenSæmundur Rögnvaldsson, Sigrun Thorsteinsdóttir, Elisavet Syriopoulou, et al.
Blood|November 21, 2024
Serum free light chains in a racially diverse population including African Americans and populations from South AfricaLuca Bertamini, Jean-Baptiste Alberge, David J Lee, et al.
Pageof 10